MA54900A - Composés inhibiteurs de l'échangeur sodium-hydrogène 3 - Google Patents

Composés inhibiteurs de l'échangeur sodium-hydrogène 3

Info

Publication number
MA54900A
MA54900A MA054900A MA54900A MA54900A MA 54900 A MA54900 A MA 54900A MA 054900 A MA054900 A MA 054900A MA 54900 A MA54900 A MA 54900A MA 54900 A MA54900 A MA 54900A
Authority
MA
Morocco
Prior art keywords
sodium
inhibitor compounds
hydrogen exchanger
exchanger
hydrogen
Prior art date
Application number
MA054900A
Other languages
English (en)
Inventor
Kostas Gavardinas
Prabhakar Jadhav
Xiaojun Wang
John Rowley Wetterau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA54900A publication Critical patent/MA54900A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
MA054900A 2019-05-16 2020-05-08 Composés inhibiteurs de l'échangeur sodium-hydrogène 3 MA54900A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962848652P 2019-05-16 2019-05-16

Publications (1)

Publication Number Publication Date
MA54900A true MA54900A (fr) 2022-03-23

Family

ID=70919092

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054900A MA54900A (fr) 2019-05-16 2020-05-08 Composés inhibiteurs de l'échangeur sodium-hydrogène 3

Country Status (14)

Country Link
US (2) US12428377B2 (fr)
EP (1) EP3921308B1 (fr)
JP (1) JP7194848B2 (fr)
KR (2) KR102681183B1 (fr)
CN (1) CN113784956B (fr)
AU (1) AU2020276204B2 (fr)
BR (1) BR112021019936A2 (fr)
EA (1) EA202192414A1 (fr)
ES (1) ES2927100T3 (fr)
IL (1) IL287963B2 (fr)
MA (1) MA54900A (fr)
MX (1) MX2021013771A (fr)
SA (1) SA521430837B1 (fr)
WO (1) WO2020231770A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805202A (zh) * 2021-01-28 2022-07-29 江西济民可信集团有限公司 苯磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
US10934280B2 (en) 2016-08-15 2021-03-02 Eli Lilly And Company Condensed thiophene derivatives useful as NaPi-IIb inhibitors
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.

Also Published As

Publication number Publication date
KR20240110086A (ko) 2024-07-12
AU2020276204A1 (en) 2021-10-07
EA202192414A1 (ru) 2022-03-02
CN113784956A (zh) 2021-12-10
EP3921308A1 (fr) 2021-12-15
US12428377B2 (en) 2025-09-30
IL287963B2 (en) 2025-01-01
US20250382271A1 (en) 2025-12-18
JP7194848B2 (ja) 2022-12-22
KR102681183B1 (ko) 2024-07-04
US20220213042A1 (en) 2022-07-07
CN113784956B (zh) 2025-03-11
BR112021019936A2 (pt) 2021-12-07
CA3136060A1 (fr) 2020-11-19
AU2020276204B2 (en) 2022-05-19
IL287963B1 (en) 2024-09-01
JP2022531438A (ja) 2022-07-06
WO2020231770A1 (fr) 2020-11-19
KR20210151911A (ko) 2021-12-14
ES2927100T3 (es) 2022-11-02
EP3921308B1 (fr) 2022-08-03
IL287963A (en) 2022-01-01
MX2021013771A (es) 2021-12-10
SA521430837B1 (ar) 2024-10-29

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA52942A (fr) Composés inhibiteurs d'oga
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
EP3941898C0 (fr) Composés fongicides
MA52493A (fr) Sels d'un inhibiteur de fgfr
MA47420A (fr) Composés inhibiteurs d'oga
EP3919491A4 (fr) Inhibiteur d'akt
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3733341A4 (fr) Magasin d'outils d'une machine-outil
EP4080151C0 (fr) Échangeur de chaleur
DK4045863T3 (da) Varmeveksler
MA54521A (fr) Dérivés d'oxopyridine substitués
PL3971508T3 (pl) Wymiennik ciepła
EP3820980A4 (fr) Compositions d'esterquats
EP4005306A4 (fr) Configuration d'intervalle de duplex intégral
EP3908319A4 (fr) Composés inhibiteurs de métalloenzyme
EP4003986A4 (fr) Composés inhibiteurs
EP3833342A4 (fr) Composés d'imidazotétrazine
EP4206080A4 (fr) Dégazeur
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3935037A4 (fr) Utilisation de composés de 8,9-dihydrocannabidiol
EP3877475A4 (fr) Compositions synergiques d'inhibiteur de corrosion
EP3859248A4 (fr) Unité d'échange de chaleur
MA52934A (fr) Composés inhibiteurs de l'oga
MA52937A (fr) Composés inhibiteurs d'oga